ArticleJournal of neurology2016
Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study.
Article in Journal of neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 62 citations in OpenAlex.
- Optic neuritis: a comprehensive review of current therapies and emerging treatment strategies.Frontiers in neurology · 2025Review
- Treatment of neuromyelitis optica spectrum disorder: revisiting the complement system and other aspects of pathogenesis.Wiener medizinische Wochenschrift (1946) · 2024Review
- Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.Journal of neurology · 2024Review
- Double-negative neuromyelitis optica spectrum disorder.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Review
- Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.Journal of neurology · 2023Review
- Prophylactic Glatiramer Acetate Treatment Positively Attenuates Spontaneous Opticospinal Encephalomyelitis.Cells · 2023Article
- Multiple Sclerosis Followed by Neuromyelitis Optica Spectrum Disorder: From the National Multiple Sclerosis Society Case Conference Proceedings.Neurology(R) neuroimmunology & neuroinflammation · 2023Article
- Immunoadsorption as maintenance therapy for refractory neuromyelitis optica spectrum disorder.Therapeutic advances in neurological disorders · 2023Article
- Review
- Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients.International journal of molecular sciences · 2020Review
- Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- Sex differences in autoimmune disorders of the central nervous system.Seminars in immunopathology · 2019Review
- Cognitive Impairment in Neuromyelitis Optica Spectrum Disorders: A Review of Clinical and Neuroradiological Features.Frontiers in neurology · 2019Review
- Review
- Pediatric Neuromyelitis Optica Spectrum Disorders.Current treatment options in neurology · 2018Review
- Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy.The EPMA journal · 2018Review
- Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis.Frontiers in neurology · 2018Review
- Optical coherence tomography in central nervous system demyelinating diseases related optic neuritis.International journal of ophthalmology · 2018Article
- [Optical coherence tomography in neuromyelitis optica spectrum disorders].Der Nervenarzt · 2017Review
- Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases.The EPMA journal · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 10 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glatiramer acetate (GA) is an approved therapy for relapsing-remitting multiple sclerosis, but its efficacy for the prevention of attacks in neuromyelitis optica spectrum disorder (NMOSD) remains unknown. We did a multicenter retrospective analysis of GA-treated patients with NMOSD, identified through a national registry. Annualized relapse rate and expanded disability status scale (EDSS) were the main outcome measures. We identified 23 GA-treated patients (21 female, 16 aquaporin-4 antibody-positive). GA was given for <6 months in seven patients; reasons for stopping were relapses (n = 3), confirmation of NMOSD (n = 2) and side effects (n = 2). Of 16 patients treated ≥ 6 months with GA (15 female, 11 aquaporin-4 antibody-positive), 14 experienced at least one relapse. There was no reduction in the mean annualized relapse rate in the total group (1.9 ± 1.1 before vs. 1.8 ± 1.4 during GA therapy), as well as in those patients who were aquaporin-4 antibody-positive, or had a history of prior immunotherapy or not. The median EDSS increased (2.5 start vs. 3.5 finish of GA, P < 0.05). GA therapy was discontinued in 15/16 patients; reasons were therapeutic inefficacy in 13 and post-injection skin reactions in two patients. We conclude that GA is not beneficial for preventing attacks in most patients with NMOSD, particularly in aquaporin-4 antibody-positive cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.